the Center for Translational Cancer Research
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Pancreatic cancer: New drug extends lives but isn't a cure
Pancreatic cancer: New drug extends lives but isn't a cure June 8, 2026Pancreatic cancer is notoriously difficult to treat — and in many cases leads to death just months after diagnosis. So it is no surprise that this headline created a stir: In a recent study, a new drug, daraxonrasib, was able to double the survival time of patients with pancreatic cancer. Compared with patients who underwent chemotherapy, those treated with daraxonrasib not only lived longer, but also reported a better...
The world will be 100 million cancer workers short by 2050, according to Lancet
A new report warns the world is heading towards a cancer care crisis, with cases sharply rising and the workforce failing to keep pace. The world will need nearly 100 million more cancer workers by 2050, a new study warns. The largest gaps will be among nurses and diagnostic specialists, particularly radiologists and pathologists, with Africa and Asia set to be the hardest hit.
AI brews a caffeine-powered safety switch for future cell therapies
AI brews a caffeine-powered safety switch for future cell therapies Gaby Clark Scientific Editor Robert Egan Associate Editor For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines. A team at the Texas A&M Health Institute of Biosciences and Technology has developed an artificial intelligence-designed molecular switch that uses caffeine to rapidly separate engineered proteins...
The secret reason some cancer treatments stop working
The secret reason some cancer treatments stop working - Date: - June 9, 2026 - Source: - University of Montreal - Summary: - Scientists have uncovered a hidden immune system "brake" that may help cancers avoid being destroyed. The molecule, called SLAMF6, weakens the body's cancer-fighting T cells and can leave them exhausted over time. Researchers developed antibodies that block this brake, allowing immune cells to stay stronger and attack tumors more effectively in mice.
Scientists uncover RNA's hidden role as protein chaperone
Scientists uncover RNA's hidden role as protein chaperone Gaby Clark Scientific Editor Andrew Zinin Lead Editor Proteins are how cells get work done. They carry out nearly every important cellular task, from ferrying messages to controlling which genes are turned on or off. And in order for proteins to perform their various roles, the strings of amino acids that make them up need to be folded into the correct shape.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.
Light-induced quantum friction of carbon nanotubes in water
Abstract Friction slows down moving objects at both macroscopic and microscopic scales1. At the electronic level, quantum friction describes direct transfer of momentum between a liquid and the electrons of a solid2. Owing to its microscopic nature, this phenomenon remains experimentally challenging to capture3.
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...